The Efficacy and Safety of Empagliflozin - Linagliptin and Empagliflozin- Metformin Therapy in Reduction of Body Weight in Type 2 Diabetic Patients .
NCT ID: NCT07247656
Last Updated: 2025-11-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
200 participants
INTERVENTIONAL
2022-12-01
2023-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient
NCT06145360
Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes
NCT06759922
Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes
NCT01984606
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
NCT01734785
Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes
NCT02686476
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
SPSS version 25 will be used to generate the descriptive statistics. Frequency and percentage figures will be used to represent the qualitative factors.
The comparison will be done between male of group A with male of group B and female of group A with female of group B.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
The study was be ethically approved by the Bahria University ethical review committee (BUMDC). Informed consent was taken before initiating the clinical trial in male and female diabetic patients.
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group B received Empagliflozin with Linagliptin
Empagliflozin 10 mg, along with Tab Linagliptin 5mg.
(Empagliflozin 10 mg+ Tab Linagliptin 5mg)
(Empagliflozin 10 mg+ Tab Linagliptin 5mg)was given once Orally daily
Group A received Empagliflozin with Metformin
Tab Empagliflozin 10 mg once daily, along with combination of Tab Metformin 500 mg
Tab Empagliflozin 10 mg + Tab Metformin 500 mg
Tab Empagliflozin 10 mg once daily, along with combination of Tab Metformin 500 mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
(Empagliflozin 10 mg+ Tab Linagliptin 5mg)
(Empagliflozin 10 mg+ Tab Linagliptin 5mg)was given once Orally daily
Tab Empagliflozin 10 mg + Tab Metformin 500 mg
Tab Empagliflozin 10 mg once daily, along with combination of Tab Metformin 500 mg
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HBA1C -(6.5-9 )percent
* All diabetic patients were BMI ≥25kg/m2
* Patient took metformin ≥1000mg/day for ≥ 3 months with uncontrolled DM
Exclusion Criteria
* Diabetic patient taking oral medicine other than metformin for last 12 weeks
* Subjects with creatinine \>1.5mg/dl
* Pregnant or Lactating Women
* Co-morbidities -
* CLD
* Cancer patient
40 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bahria University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Nabila Rafi
MBBS , M.PHIL PHARMACOLOGY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
NABILA RAFI
Role: PRINCIPAL_INVESTIGATOR
DOCTOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bahria University
Karachi, Sindh, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ERC 105/2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.